Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 22 May 1998:
Vol. 280. no. 5367, pp. 1196 - 1197
DOI: 10.1126/science.280.5367.1196
Prev | Table of Contents | Next

Research News

CANCER THERAPY:
Antibodies Stage a Comeback in Cancer Treatment

Steven Dickman

In 1982, an immunologist reported vanquishing cancer in a patient using antibodies custom-designed to attack his own lymphoma cells, but in subsequent testing of other antibodies, the effects in humans didn't match those in mice and unexpected toxicity even killed patients, bringing clinical trials to an abrupt halt. Now, the U.S. Food and Drug Administration has approved an antilymphoma antibody, and just last week, researchers announced some success with an antibody tailored to fight recalcitrant breast cancers that is nearing regulatory approval. But researchers caution that antibodies will never replace conventional cancer chemotherapy drugs; in fact, results so far show that they may work best when combined with those drugs.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
BAT mAb induces lymphopoiesis in nude mice.
B. Hardy, Y. Niv, L. Fadaeev, and A. Raiter (2005)
Int. Immunol. 17, 615-619
   Abstract »    Full Text »    PDF »
Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells.
T. M. Trost, E. U. Lausch, S. A. Fees, S. Schmitt, T. Enklaar, D. Reutzel, L. R. Brixel, P. Schmidtke, M. Maringer, I. B. Schiffer, et al. (2005)
Cancer Res. 65, 840-849
   Abstract »    Full Text »    PDF »
Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission.
I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al. (2003)
Cancer Res. 63, 7221-7231
   Abstract »    Full Text »    PDF »
Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer.
W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price (2003)
Clin. Chem. 49, 1579-1598
   Abstract »    Full Text »    PDF »
Enhanced Sensitization to Taxol-induced Apoptosis by Herceptin Pretreatment in ErbB2-overexpressing Breast Cancer Cells.
S. Lee, W. Yang, K.-H. Lan, S. Sellappan, K. Klos, G. Hortobagyi, M.-C. Hung, and D. Yu (2002)
Cancer Res. 62, 5703-5710
   Abstract »    Full Text »    PDF »
Anti-interleukin 6 receptor antibody treatment in rheumatic disease.
N. Nishimoto, T. Kishimoto, and K. Yoshizaki (2000)
Ann Rheum Dis 59, i21-27
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)